Breadcrumb AMCP.org Policy & Advocacy Letters, Statements & Analysis AMCP Submitted Comments to the FDA on Updated Draft Guidance on Nonproprietary Naming of Biologics AMCP Submitted Comments to the FDA on Updated Draft Guidance on Nonproprietary Naming of Biologics 5/7/19 Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page AMCP Submitted Comments to the FDA on Updated Draft Guidance on Nonproprietary Naming of Biologics.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page